|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the
year 2020: An overview. Int J Cancer: Apr 5, 2021 (Epub ahead of
print).
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global CANCER Statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Deo SVS, Sharma J and Kumar S: GLOBOCAN
2020 report on global cancer burden: Challenges and opportunities
for surgical oncologists. Ann Surg Oncol. 29:6497–6500.
2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Cao W, Chen HD, Yu YW, Li N and Chen WQ:
Changing profiles of cancer burden worldwide and in China: A
secondary analysis of the global cancer statistics 2020. Chin Med J
(Engl). 134:783–791. 2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wang M, Herbst RS and Boshoff C: Toward
personalized treatment approaches for non-small-cell lung cancer.
Nat Med. 27:1345–1356. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mattiuzzi C and Lippi G: Cancer
statistics: A comparison between World Health Organization (WHO)
and global burden of disease (GBD). Eur J Public Health.
30:1026–1027. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Xi KX, Zhang XW, Yu XY, Wang WD, Xi KX,
Chen YQ, Wen YS and Zhang LJ: The role of plasma miRNAs in the
diagnosis of pulmonary nodules. J Thorac Dis. 10:4032–4041.
2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Nooreldeen R and Bach H: Current and
future development in lung cancer diagnosis. Int J Mol Sci.
22(8661)2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wen M, Wang L, Wang X, Yang S, Sun Y, Xia
J, Zhang Y, Zhang Z, Huang L and Jiang T: Optimal adjuvant therapy
in resected stage IIIA-N2 non-small-cell lung cancer harboring EGFR
mutations. Oncol Res Treat. 43:686–693. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wei
YC, Liu YY, Chen C, Cheng Y, Yin R, et al: Gefitinib versus
vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA
(N1-N2) EGFR-mutant NSCLC: final overall survival analysis of
CTONG1104 phase III trial. J Clin Oncol. 39:713–722.
2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Colletti PM: Earlier diagnosis of
subcentimeter lung cancers is not self-evidently beneficial:
Personal experience. AJR Am J Roentgenol. 213:819–820.
2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Shin KE, Lee KS, Yi CA, Chung MJ, Shin MH
and Choi YH: Subcentimeter lung nodules stable for 2 years at LDCT:
Long-term follow-up using volumetry. Respirology. 19:921–928.
2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Heuvelmans MA, Groen HJ and Oudkerk M:
Early lung cancer detection by low-dose CT screening: Therapeutic
implications. Expert Rev Respir Med. 11:89–100. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Reich JM and Kim JS: Earlier diagnosis not
self-evidently beneficial: Natural history of subcentimeter lung
cancers. AJR Am J Roentgenol. 213:817–818. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Parikh AR: Lung cancer genomics. Acta Med
Acad. 48:78–83. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Imyanitov EN, Iyevleva AG and Levchenko
EV: Molecular testing and targeted therapy for non-small cell lung
cancer: Current status and perspectives. Crit Rev Oncol Hematol.
157(103194)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rammal S, Kourie HR, Jalkh N, Mehawej C,
Chouery E, Moujaess E and Dabar G: Molecular pathogenesis of
hereditary lung cancer: A literature review. Pharmacogenomics.
22:791–803. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hu B, Ren W, Feng Z, Li M, Li X, Han R and
Peng Z: Correlation between CT imaging characteristics and
pathological diagnosis for subcentimeter pulmonary nodules. Thorac
Cancer. 13:1067–1075. 2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ruiz-Cordero R and Devine WP: Targeted
therapy and checkpoint immunotherapy in lung cancer. Surg Pathol
Clin. 13:17–33. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Miller M and Hanna N: Advances in systemic
therapy for non-small cell lung cancer. BMJ.
375(n2363)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Schuler M, Bölükbas S, Darwiche K,
Theegarten D, Herrmann K and Stuschke M: Personalized treatment for
patients with lung cancer. Dtsch Arztebl Int: arztebl.m2023.012,
2023 (Epub ahead of print).
|
|
22
|
Wu F, Wang L and Zhou C: Lung cancer in
China: Current and prospect. Curr Opin Oncol. 33:40–46.
2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Sherry V: Lung cancer: Prevention and
early identification are key. Nurse Pract. 47:42–47.
2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Mazzone PJ and Lam L: Evaluating the
patient with a pulmonary nodule: A review. JAMA. 327:264–273.
2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hansell DM, Bankier AA, Macmahon H, McLoud
TC, Müller NL and Remy J: Fleischner Society: glossary of terms for
thoracic imaging. Radiology. 246:697–722. 2008.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Li H, Sun Z, Li Y, Qi Q, Huang H, Wang X,
Zhou J, Liu K, Yin P, Wang Z, et al: Disparate genomic
characteristics of patients with early-stage lung adenocarcinoma
manifesting as radiological subsolid or solid lesions. Lung Cancer.
166:178–188. 2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Lv Y and Ye B: Advances in diagnosis and
management of subcentimeter pulmonary nodules. Zhongguo Fei Ai Za
Zhi. 23:365–370. 2020.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
28
|
Callister ME, Baldwin DR, Akram AR,
Barnard S, Cane P, Draffan J, Franks K, Gleeson F, Graham R,
Malhotra P, et al: British Thoracic Society guidelines for the
investigation and management of pulmonary nodules. Thorax. 70
(Suppl 2):ii1–ii54. 2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Armstrong C: Lung cancer screening
recommendations from the ACCP. Am Fam Physician. 98:688–689.
2018.PubMed/NCBI
|
|
30
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico
TA, et al: Non-small cell lung cancer, version 3.2022, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
20:497–530. 2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Oncology Society of Chinese Medical
Association; Chinese Medical Association Publishing House. Chinese
medical association guideline for clinical diagnosis and treatment
of lung cancer (2022 edition). Zhonghua Zhong Liu Za Zhi.
44:457–490. 2022.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
32
|
Suzuki K, Watanabe SI, Wakabayashi M, Saji
H, Aokage K, Moriya Y, Yoshino I, Tsuboi M, Nakamura S, Nakamura K,
et al: A single-arm study of sublobar resection for ground-glass
opacity dominant peripheral lung cancer. J Thorac Cardiovasc Surg.
163:289–301.e2. 2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Borghesi A, Michelini S, Nocivelli G,
Silva M, Scrimieri A, Pezzotti S, Maroldi R and Farina D: Solid
indeterminate pulmonary nodules less than or equal to 250
mm3: Application of the updated fleischner society
guidelines in clinical practice. Radiol Res Pract.
2019(7218258)2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Borghesi A, Michelini S, Scrimieri A,
Golemi S and Maroldi R: Solid indeterminate pulmonary nodules of
less than 300 mm3: Application of different volume
doubling time cut-offs in clinical practice. Diagnostics (Basel).
9(62)2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhan Y, Peng X, Shan F, Feng M, Shi Y, Liu
L and Zhang Z: Attenuation and morphologic characteristics
distinguishing a ground-glass nodule measuring 5-10 mm in diameter
as invasive lung adenocarcinoma on thin-slice CT. AJR Am J
Roentgenol. 213:W162–W170. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Hui H, Yin HT, Wang T and Chen G: Computed
tomography-guided core needle biopsy for sub-centimeter pulmonary
nodules. Kardiochir Torakochirurgia Pol. 19:65–69. 2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Chen W, Li M, Mao D, Ge X, Wang J, Tan M,
Ma W, Huang X, Lu J, Li C, et al: Radiomics signature on CECT as a
predictive factor for invasiveness of lung adenocarcinoma
manifesting as subcentimeter ground glass nodules. Sci Rep.
11(3633)2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Kutob L and Schneider F: Lung cancer
staging. Surg Pathol Clin. 13:57–71. 2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Pasic A, Postmus PE and Sutedja TG: What
is early lung cancer? A review of the literature. Lung Cancer.
45:267–77. 2004.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Mi J, Wang S, Li X and Jiang G: Clinical
characteristics and prognosis of sub-centimeter lung
adenocarcinoma. Zhongguo Fei Ai Za Zhi. 22:500–506. 2019.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
41
|
Shen C, Wu Q, Xia Q, Cao C, Wang F, Li Z
and Fan L: Establishment of a malignancy and benignancy prediction
model of sub-centimeter pulmonary ground-glass nodules based on the
inflammation-cancer transformation theory. Front Med (Lausanne).
9(1007589)2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ginsberg RJ and Rubinstein LV: Randomized
trial of lobectomy versus limited resection for T1 N0 non-small
cell lung cancer. Lung cancer study group. Ann Thorac Surg.
60:615–623. 1995.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Jiang W, Pang X, Xi J, Chen X, Wang Q,
Qian C and Fan H: Clinical outcome of subcentimeter non-small cell
lung cancer after surgical resection: Single institution experience
of 105 patients. J Surg Oncol. 110:233–238. 2014.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Bai W, Zhang J, Wang Y, Zhou M, Liu L,
Wang G, Zhao K, Gao X and Li S: Comparative analysis of the
long-term outcomes of segmentectomy and lobectomy for stage IA1
lung adenocarcinoma in patients with or without previous malignancy
of other organs: A population-based study. Expert Rev Anticancer
Ther. 22:215–228. 2022.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Saji H, Okada M, Tsuboi M, Nakajima R,
Suzuki K, Aokage K, Aoki T, Okami J, Yoshino I, Ito H, et al:
Segmentectomy versus lobectomy in small-sized peripheral
non-small-cell lung cancer (JCOG0802/WJOG4607L): A multicentre,
open-label, phase 3, randomised, controlled, non-inferiority trial.
Lancet. 399:1607–1617. 2022.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Altorki N, Wang X, Kozono D, Watt C,
Landrenau R, Wigle D, Port J, Jones DR, Conti M, Ashrafi AS, et al:
Lobar or sublobar resection for peripheral stage IA non-small-cell
lung cancer. N Engl J Med. 388:489–498. 2023.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Miyajima M, Maki R, Arai W, Tsuruta K,
Shindo Y, Nakamura Y and Watanabe A: Robot-assisted vs
video-assisted thoracoscopic surgery in lung cancer. J Thorac Dis.
14:1890–1899. 2022.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Qi F, Xiang M, Deng Y, Huang W and Sun Y:
Application of Da Vinci Robot and thoracoscopy in radical lung
cancer surgery. J Healthc Eng. 2022(2011062)2022.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Shimomura M, Ishihara S and Inoue M:
Robot-assisted segmentectomy for lung cancer. Kyobu Geka. 76:79–83.
2023.PubMed/NCBI(In Japanese).
|
|
50
|
Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR,
Threapleton D, Yang ZY, Mao C and Tang JL: The prevalence of EGFR
mutation in patients with non-small cell lung cancer: A systematic
review and meta-analysis. Oncotarget. 7:78985–78993.
2016.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Harrison PT, Vyse S and Huang PH: Rare
epidermal growth factor receptor (EGFR) mutations in non-small cell
lung cancer. Semin Cancer Biol. 61:167–179. 2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Rosell R, Cardona AF, Arrieta O, Aguilar
A, Ito M, Pedraz C, Codony-Servat J and Santarpia M: Coregulation
of pathways in lung cancer patients with EGFR mutation: Therapeutic
opportunities. Br J Cancer. 125:1602–1611. 2021.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Chen YJ, Roumeliotis TI, Chang YH, Chen
CT, Han CL, Lin MH, Chen HW, Chang GC, Chang YL, Wu CT, et al:
Proteogenomics of non-smoking lung cancer in east asia delineates
molecular signatures of pathogenesis and progression. Cell.
182:226–244.e17. 2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Chang YS, Tu SJ, Chen YC, Liu TY, Lee YT,
Yen JC, Fang HY and Chang JG: Mutation profile of non-small cell
lung cancer revealed by next generation sequencing. Respir Res.
22(3)2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Tsubata Y, Tanino R and Isobe T: Current
therapeutic strategies and prospects for EGFR mutation-positive
lung cancer based on the mechanisms underlying drug resistance.
Cells. 10(3192)2021.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Yang JC, Sequist LV, Geater SL, Tsai CM,
Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, et al:
Clinical activity of afatinib in patients with advanced
non-small-cell lung cancer harbouring uncommon EGFR mutations: A
combined post-hoc analysis of LUX-lung 2, LUX-lung 3, and LUX-lung
6. Lancet Oncol. 16:830–838. 2015.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Noronha V, Patil VM, Joshi A, Menon N,
Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, et al:
Gefitinib versus gefitinib plus pemetrexed and carboplatin
chemotherapy in EGFR-mutated lung cancer. J Clin Oncol. 38:124–136.
2020.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Gerber DE, Mayer M, Gagan J and von
Itzstein MS: Systemic and intracranial efficacy of osimertinib in
EGFR L747P-mutant NSCLC: Case report. JTO Clin Res Rep.
3(100291)2022.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Miyauchi E, Morita S, Nakamura A, Hosomi
Y, Watanabe K, Ikeda S, Seike M, Fujita Y, Minato K, Ko R, et al:
Updated analysis of NEJ009: Gefitinib-alone versus gefitinib plus
chemotherapy for non-small-cell lung cancer with mutated EGFR. J
Clin Oncol. 40:3587–3592. 2022.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Shirley M and Keam SJ: Aumolertinib: A
review in non-small cell lung cancer. Drugs. 82:577–584.
2022.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Wang J and Wu L: An evaluation of
aumolertinib for the treatment of EGFR T790M mutation-positive
non-small cell lung cancer. Expert Opin Pharmacother. 23:647–652.
2022.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Wu YL, Tsuboi M, He J, John T, Grohe C,
Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, et al:
Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N
Engl J Med. 383:1711–1723. 2020.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Wen S, Dai L, Wang L, Wang W, Wu D, Wang
K, He Z, Wang A, Chen H, Zhang P, et al: Genomic signature of
driver genes identified by target next-generation sequencing in
Chinese non-small cell lung cancer. Oncologist. 24:e1070–e1081.
2019.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Bernabé-Caro R, Garrido P, García-Campelo
R, Palmero R, Artal Á, Bayona C, Rodríguez-Abreu D, López-Brea M,
Paredes A, Vicente D, et al: Alectinib after failure to crizotinib
in patients with ALK-positive non-small cell lung cancer: Results
from the Spanish early access program. Oncotarget. 13:812–827.
2022.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Hotta K, Hida T, Nokihara H, Morise M, Kim
YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, et al:
Final overall survival analysis from the phase III J-ALEX study of
alectinib versus crizotinib in ALK inhibitor-naïve Japanese
patients with ALK-positive non-small-cell lung cancer. ESMO Open.
7(100527)2022.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Horn L, Wang Z, Wu G, Poddubskaya E, Mok
T, Reck M, Wakelee H, Chiappori AA, Lee DH, Breder V, et al:
Ensartinib vs crizotinib for patients with anaplastic lymphoma
kinase-positive non-small cell lung cancer: A randomized clinical
trial. JAMA Oncol. 7:1617–1625. 2021.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Negrao MV, Skoulidis F, Montesion M,
Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, et al:
Oncogene-specific differences in tumor mutational burden, PD-L1
expression, and outcomes from immunotherapy in non-small cell lung
cancer. J Immunother Cancer. 9(e002891)2021.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Riudavets M, Cascetta P and Planchard D:
Targeting BRAF-mutant non-small cell lung cancer: Current status
and future directions. Lung Cancer. 169:102–114. 2022.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Tan AC and Tan DSW: Targeted therapies for
lung cancer patients with oncogenic driver molecular alterations. J
Clin Oncol. 40:611–625. 2022.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Kelly RJ: Dabrafenib and trametinib for
the treatment of non-small cell lung cancer. Expert Rev Anticancer
Ther. 18:1063–1068. 2018.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Zhuang X, Zhao C, Li J, Su C, Chen X, Ren
S, Li X and Zhou C: Clinical features and therapeutic options in
non-small cell lung cancer patients with concomitant mutations of
EGFR, ALK, ROS1, KRAS or BRAF. Cancer Med. 8:2858–2866.
2019.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Parekh PR, Botting GM, Thurber DB,
Boruszczak M, Murphy W and Bertenshaw GP: Predictive biomarkers for
response to trametinib in non-small cell lung cancer. Tumour Biol.
44:249–267. 2022.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Planchard D, Besse B, Groen HJM, Hashemi
SMS, Mazieres J, Kim TM, Quoix E, Souquet PJ, Barlesi F, Baik C, et
al: Phase 2 study of dabrafenib plus trametinib in patients with
BRAF V600E-mutant metastatic NSCLC: Updated 5-year survival rates
and genomic analysis. J Thorac Oncol. 17:103–115. 2022.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Yang SR, Schultheis AM, Yu H, Mandelker D,
Ladanyi M and Büttner R: Precision medicine in non-small cell lung
cancer: Current applications and future directions. Semin Cancer
Biol. 84:184–198. 2022.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Zhu X, Lu Y and Lu S: Landscape of
savolitinib development for the treatment of non-small cell lung
cancer with MET alteration-A narrative review. Cancers (Basel).
14(6122)2022.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Lu S, Fang J, Li X, Cao L, Zhou J, Guo Q,
Liang Z, Cheng Y, Jiang L, Yang N, et al: Once-daily savolitinib in
Chinese patients with pulmonary sarcomatoid carcinomas and other
non-small-cell lung cancers harbouring MET exon 14 skipping
alterations: A multicentre, single-arm, open-label, phase 2 study.
Lancet Respir Med. 9:1154–1164. 2021.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Shaw AT, Riely GJ, Bang YJ, Kim DW,
Camidge DR, Solomon BJ, Varella-Garcia M, Iafrate AJ, Shapiro GI,
Usari T, et al: Crizotinib in ROS1-rearranged advanced
non-small-cell lung cancer (NSCLC): Updated results, including
overall survival, from PROFILE 1001. Ann Oncol. 30:1121–1126.
2019.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Salgia R, Pharaon R, Mambetsariev I, Nam A
and Sattler M: The improbable targeted therapy: KRAS as an emerging
target in non-small cell lung cancer (NSCLC). Cell Rep Med.
2(100186)2021.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Luo J, Ostrem J, Pellini B, Imbody D,
Stern Y, Solanki HS, Haura EB and Villaruz LC: Overcoming
KRAS-mutant lung cancer. Am Soc Clin Oncol Educ Book. 42:1–11.
2022.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Tsubokawa N, Tsutani Y, Miyata Y, Handa Y,
Misumi K, Hanaki H, Hida E and Okada M: Segmentectomy versus
lobectomy for radiologically pure solid clinical T1a-bN0M0 lung
cancer. World J Surg. 42:2493–2501. 2018.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Skoulidis F and Heymach JV: Co-occurring
genomic alterations in non-small-cell lung cancer biology and
therapy. Nat Rev Cancer. 19:495–509. 2019.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Drusbosky LM, Rodriguez E, Dawar R and
Ikpeazu CV: Therapeutic strategies in RET gene rearranged non-small
cell lung cancer. J Hematol Oncol. 14(50)2021.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Gainor JF, Curigliano G, Kim DW, Lee DH,
Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, et al:
Pralsetinib for RET fusion-positive non-small-cell lung cancer
(ARROW): A multi-cohort, open-label, phase 1/2 study. Lancet Oncol.
22:959–969. 2021.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Jiao XD, Qin BD, You P, Cai J and Zang YS:
The prognostic value of TP53 and its correlation with EGFR mutation
in advanced non-small cell lung cancer, an analysis based on
cBioPortal data base. Lung Cancer. 123:70–55. 2018.PubMed/NCBI View Article : Google Scholar
|
|
85
|
La Fleur L, Falk-Sörqvist E, Smeds P,
Berglund A, Sundström M, Mattsson JS, Brandén E, Koyi H, Isaksson
J, Brunnström H, et al: Mutation patterns in a population-based
non-small cell lung cancer cohort and prognostic impact of
concomitant mutations in KRAS and TP53 or STK11. Lung Cancer.
130:50–58. 2019.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Xu F, Lin H, He P, He L, Chen J, Lin L and
Chen Y: A TP53-associated gene signature for prediction of
prognosis and therapeutic responses in lung squamous cell
carcinoma. Oncoimmunology. 9(1731943)2020.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Abbosh C, Venkatesan S, Janes SM,
Fitzgerald RC and Swanton C: Evolutionary dynamics in pre-invasive
neoplasia. Curr Opin Syst Biol. 2:1–8. 2017.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Sivakumar S, San Lucas FA, Jakubek YA,
McDowell TL, Lang W, Kallsen N, Peyton S, Davies GE, Fukuoka J,
Yatabe Y, et al: Genomic landscape of allelic imbalance in
premalignant atypical adenomatous hyperplasias of the lung.
EBioMedicine. 42:296–303. 2019.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Chen H, Carrot-Zhang J, Zhao Y, Hu H,
Freeman SS, Yu S, Ha G, Taylor AM, Berger AC, Westlake L, et al:
Genomic and immune profiling of pre-invasive lung adenocarcinoma.
Nat Commun. 10(5472)2019.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Hu X, Fujimoto J, Ying L, Fukuoka J,
Ashizawa K, Sun W, Reuben A, Chow CW, McGranahan N, Chen R, et al:
Multi-region exome sequencing reveals genomic evolution from
preneoplasia to lung adenocarcinoma. Nat Commun.
10(2978)2019.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Zhang C, Zhang J, Xu FP, Wang YG, Xie Z,
Su J, Dong S, Nie Q, Shao Y, Zhou Q, et al: Genomic landscape and
immune microenvironment features of preinvasive and early invasive
lung adenocarcinoma. J Thorac Oncol. 14:1912–1923. 2019.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Yu F, Peng M, Bai J, Zhu X, Zhang B, Tang
J, Liu W, Chen C, Wang X, Chen M, et al: Comprehensive
characterization of genomic and radiologic features reveals
distinct driver patterns of RTK/RAS pathway in ground-glass opacity
pulmonary nodules. Int J Cancer. 151:2020–2030. 2022.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Li Y, Li X, Li H, Zhao Y, Liu Z, Sun K,
Zhu X, Qi Q, An B, Shen D, et al: Genomic characterisation of
pulmonary subsolid nodules: Mutational landscape and radiological
features. Eur Respir J. 55(1901409)2020.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Chen K, Bai J, Reuben A, Zhao H, Kang G,
Zhang C, Qi Q, Xu Y, Hubert S, Chang L, et al: Multiomics analysis
reveals distinct immunogenomic features of lung cancer with
ground-glass opacity. Am J Respir Crit Care Med. 204:1180–1192.
2021.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Saito M, Suzuki H, Kono K, Takenoshita S
and Kohno T: Treatment of lung adenocarcinoma by molecular-targeted
therapy and immunotherapy. Surg Today. 48:1–8. 2018.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Schoenfeld AJ, Bandlamudi C, Lavery JA,
Montecalvo J, Namakydoust A, Rizvi H, Egger J, Concepcion CP, Paul
S, Arcila ME, et al: The genomic landscape of SMARCA4 alterations
and associations with outcomes in patients with lung cancer. Clin
Cancer Res. 26:5701–5708. 2020.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Yu Y and Tian X: Analysis of genes
associated with prognosis of lung adenocarcinoma based on GEO and
TCGA databases. Medicine (Baltimore). 99(e20183)2020.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Li S, Choi YL, Gong Z, Liu X, Lira M, Kan
Z, Oh E, Wang J, Ting JC, Ye X, et al: Comprehensive
characterization of oncogenic drivers in asian lung adenocarcinoma.
J Thorac Oncol. 11:2129–2140. 2016.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Shi H, Seegobin K, Heng F, Zhou K, Chen R,
Qin H, Manochakian R, Zhao Y and Lou Y: Genomic landscape of lung
adenocarcinomas in different races. Front Oncol.
12(946625)2022.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Wu SG, Liu YN, Yu CJ, Yang JC and Shih JY:
Driver mutations of young lung adenocarcinoma patients with
malignant pleural effusion. Genes Chromosomes Cancer. 57:513–521.
2018.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Cancer Genome Atlas Research Network.
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Izumchenko E, Chang X, Brait M, Fertig E,
Kagohara LT, Bedi A, Marchionni L, Agrawal N, Ravi R, Jones S, et
al: Targeted sequencing reveals clonal genetic changes in the
progression of early lung neoplasms and paired circulating DNA. Nat
Commun. 6(8258)2015.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Sivakumar S, Lucas FAS, Mcdowell TL, Lang
W, Xu L, Fujimoto J, Zhang J, Futreal PA, Fukuoka J, Yatabe Y, et
al: Genomic landscape of atypical adenomatous hyperplasia reveals
divergent modes to lung adenocarcinoma. Cancer Res. 77:6119–6130.
2017.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Dejima H, Hu X, Chen R, Zhang J, Fujimoto
J, Parra ER, Haymaker C, Hubert SM, Duose D, Solis LM, et al:
Immune evolution from preneoplasia to invasive lung adenocarcinomas
and underlying molecular features. Nat Commun.
12(2722)2021.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Tanaka K, Hida T, Oya Y, Yoshida T,
Shimizu J, Mizuno T, Kuroda H, Sakakura N, Yoshimura K, Horio Y, et
al: Unique prevalence of oncogenic genetic alterations in young
patients with lung adenocarcinoma. Cancer. 123:1731–1740.
2017.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Han X, Ren P and Ma S: Bioinformatics
analysis reveals three key genes and four survival genes associated
with youth-onset NSCLC. Open Med (Wars). 17:1123–1133.
2022.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Campbell JD, Alexandrov A, Kim J, Wala J,
Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, et
al: Distinct patterns of somatic genome alterations in lung
adenocarcinomas and squamous cell carcinomas. Nat Genet.
48:607–616. 2016.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Van Dijk EL, Jaszczyszyn Y, Naquin D and
Thermes C: The third revolution in sequencing technology. Trends
Genet. 34:666–681. 2018.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Hieggelke L and Schultheis AM: Application
of FISH in the diagnosis of lung cancer. Pathologe. 41:582–588.
2020.PubMed/NCBI View Article : Google Scholar : (In German).
|
|
110
|
Su C, Liu WX, Wu LS, Dong TJ and Liu JF:
Screening of hub gene targets for lung cancer via microarray data.
Comb Chem High Throughput Screen. 24:269–285. 2021.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Morganti S, Tarantino P, Ferraro E,
D'Amico P, Viale G, Trapani D, Duso BA and Curigliano G: Complexity
of genome sequencing and reporting: Next generation sequencing
(NGS) technologies and implementation of precision medicine in real
life. Crit Rev Oncol Hematol. 133:171–182. 2019.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Xu X, Li N, Zhao R, Zhu L, Shao J and
Zhang J: Targeted next-generation sequencing for analyzing the
genetic alterations in atypical adenomatous hyperplasia and
adenocarcinoma in situ. J Cancer Res Clin Oncol. 143:2447–243.
2017.PubMed/NCBI View Article : Google Scholar
|
|
113
|
De Scordilli M, Michelotti A, Bertoli E,
De Carlo E, Del Conte A and Bearz A: Targeted therapy and
immunotherapy in early-stage non-small cell lung cancer: Current
evidence and ongoing trials. Int J Mol Sci. 23(7222)2022.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Sepesi B, Zhou N, William WN Jr, Lin HY,
Leung CH, Weissferdt A, Mitchell KG, Pataer A, Walsh GL, Rice DC,
et al: Surgical outcomes after neoadjuvant nivolumab or nivolumab
with ipilimumab in patients with non-small cell lung cancer. J
Thorac Cardiovasc Surg. 164:1327–1337. 2022.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Nagano T, Tachihara M and Nishimura Y:
Molecular mechanisms and targeted therapies including immunotherapy
for non-small cell lung cancer. Curr Cancer Drug Targets.
19:595–630. 2019.PubMed/NCBI View Article : Google Scholar
|
|
116
|
Tsutani Y, Ito M, Shimada Y, Ito H, Ikeda
N, Nakayama H and Okada M: The impact of epidermal growth factor
receptor mutation status on adjuvant chemotherapy for patients with
high-risk stage I lung adenocarcinoma. J Thorac Cardiovasc Surg.
164:1306–13015.e4. 2022.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Mazzone PJ, Gould MK, Arenberg DA, Chen
AC, Choi HK, Detterbeck FC, Farjah F, Fong KM, Iaccarino JM, Janes
SM, et al: Management of lung nodules and lung cancer screening
during the COVID-19 pandemic: CHEST expert panel report. Chest.
158:406–615. 2020.PubMed/NCBI View Article : Google Scholar
|
|
118
|
Yi QQ, Yang R, Shi JF, Zeng NY, Liang DY,
Sha S and Chang Q: Effect of preservation time of formalin-fixed
paraffin-embedded tissues on extractable DNA and RNA quantity. J
Int Med Res. 48(300060520931259)2020.PubMed/NCBI View Article : Google Scholar
|
|
119
|
Kim YH, Nishimura Y and Funada Y: How
should we manage non-small-cell lung cancer
‘not-otherwise-specified’? Med Oncol. 38(82)2021.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Liu X, Liu X, Li J and Ren F:
Identification and integrated analysis of key biomarkers for
diagnosis and prognosis of non-small cell lung cancer. Med Sci
Monit. 25:9280–9289. 2019.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Shi Y, Zhu S, Yang J, Shao M, Ding W,
Jiang W, Sun X and Yao N: Investigation of potential mechanisms
associated with non-small cell lung cancer. J Comput Biol.
27:1433–1442. 2020.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Wang L, Qu J, Liang Y, Zhao D, Rehman FU,
Qin K and Zhang X: Identification and validation of key genes with
prognostic value in non-small-cell lung cancer via integrated
bioinformatics analysis. Thorac Cancer. 11:851–866. 2020.PubMed/NCBI View Article : Google Scholar
|
